Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001242
Filing Date
2025-05-14
Accepted
2025-05-14 08:15:25
Documents
74
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20250331x10q.htm   iXBRL 10-Q 1345075
2 EX-31.1 tmb-20250331xex31d1.htm EX-31.1 15303
3 EX-32.1 tmb-20250331xex32d1.htm EX-32.1 7045
4 GRAPHIC tmb-20250331x10q001.jpg GRAPHIC 43242
  Complete submission text file 0001410578-25-001242.txt   6686444

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20250331.xsd EX-101.SCH 54115
6 EX-101.CAL tmb-20250331_cal.xml EX-101.CAL 52467
7 EX-101.DEF tmb-20250331_def.xml EX-101.DEF 189116
8 EX-101.LAB tmb-20250331_lab.xml EX-101.LAB 436915
9 EX-101.PRE tmb-20250331_pre.xml EX-101.PRE 334077
77 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20250331x10q_htm.xml XML 1069811
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 25942745
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)